Texas Permanent School Fund Raises Position in Amedisys Inc (NASDAQ:AMED)

Texas Permanent School Fund raised its stake in Amedisys Inc (NASDAQ:AMED) by 10.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 21,900 shares of the health services provider’s stock after buying an additional 2,109 shares during the quarter. Texas Permanent School Fund’s holdings in Amedisys were worth $2,869,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of AMED. FMR LLC raised its stake in shares of Amedisys by 13.4% in the first quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after purchasing an additional 43,844 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Amedisys by 91.8% in the second quarter. WINTON GROUP Ltd now owns 5,520 shares of the health services provider’s stock worth $670,000 after purchasing an additional 2,642 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Amedisys by 122.7% in the second quarter. Retirement Systems of Alabama now owns 84,431 shares of the health services provider’s stock worth $10,251,000 after purchasing an additional 46,512 shares during the last quarter. Riverbridge Partners LLC purchased a new stake in shares of Amedisys in the second quarter worth approximately $80,465,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in shares of Amedisys in the second quarter worth approximately $392,000. 88.11% of the stock is owned by hedge funds and other institutional investors.

In other Amedisys news, Director Jake L. Netterville sold 1,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $135.64, for a total value of $135,640.00. Following the completion of the sale, the director now directly owns 72,700 shares of the company’s stock, valued at $9,861,028. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christopher Gerard sold 350 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $145.15, for a total value of $50,802.50. Following the completion of the sale, the chief operating officer now directly owns 24,922 shares of the company’s stock, valued at $3,617,428.30. The disclosure for this sale can be found here. Insiders sold 2,050 shares of company stock valued at $278,696 over the last three months. Company insiders own 2.90% of the company’s stock.

NASDAQ:AMED opened at $148.33 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.95 and a quick ratio of 0.95. The business has a fifty day simple moving average of $133.29 and a two-hundred day simple moving average of $126.21. Amedisys Inc has a 1 year low of $103.76 and a 1 year high of $154.14. The company has a market capitalization of $4.73 billion, a P/E ratio of 40.86, a P/E/G ratio of 2.03 and a beta of 1.38.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.25. Amedisys had a return on equity of 26.53% and a net margin of 6.70%. The business had revenue of $494.63 million during the quarter, compared to the consensus estimate of $494.14 million. During the same period last year, the business posted $0.95 earnings per share. The business’s revenue for the quarter was up 18.5% on a year-over-year basis. As a group, analysts anticipate that Amedisys Inc will post 4.39 earnings per share for the current year.

A number of analysts recently commented on the company. Oppenheimer increased their price target on Amedisys from $140.00 to $150.00 in a research report on Thursday, August 1st. Raymond James increased their price target on Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a research report on Monday, July 15th. UBS Group increased their price target on Amedisys from $144.00 to $154.00 and gave the company a “neutral” rating in a research report on Thursday. Barclays increased their price target on Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. Finally, Deutsche Bank assumed coverage on Amedisys in a research report on Monday, September 16th. They set a “buy” rating and a $155.00 price target for the company. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $145.36.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: Capital Gains

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit